FDA Extends Safety Review of Abortion Pill Mifepristone; Advocates Express Frustration

Missoula, MT, October 8, 2026 — The U.S. Food and Drug Administration (FDA) has extended its safety review of mifepristone, an abortion pill. A report detailing the findings of this review is anticipated by March 2027.

This extended review process is a component of a larger legal proceeding that was initiated by a federal judge. The duration of the review means that definitive action or conclusions regarding the drug’s safety profile will not be immediately available.

The FDA’s decision to extend the review has reportedly led to frustration among anti-abortion advocates. These groups had been seeking an immediate curtailment of mifepristone’s use. The extended timeline means that their calls for swift action are not being met.

Specific details regarding the nature of the federal judge’s order that initiated the review process were not immediately available. Additionally, the precise reasons for the extended safety review by the FDA were not elaborated upon in the provided information.

Anti-abortion advocates had expressed a desire for the drug’s use to be curtailed promptly. The extended timeline for the FDA’s report, now set for March 2027, signifies a protracted period before any potential regulatory adjustments based on this specific safety review could be enacted. The contractor’s name involved in this review process was not provided. The fine amount related to this legal process was not provided.

Story summarized from the original created by AP via Scripps News Group on www.kpax.com, see more information here.